Research Article
Intratumoral CD3+ T-Lymphocytes Immunoexpression and Its Association with c-Kit, Angiogenesis, and Overall Survival in Malignant Canine Mammary Tumors
Table 1
Relationship of CD3/c-kit, CD3/VEGF, and c-kit/VEGF groups with clinicopathological variables of tumor aggressiveness.
| | | Variables of tumor aggressiveness |
Molecular markers | HGM | Neoplastic intravascular emboli | Lymph node metastasis | | | Low (I/II) | High (III) | | Absent | Present | | Absent | Present | |
|
CD3/c-kit | Low CD3/low c-kit | 18 | 4 |
<0.0001 | 20 | 2 |
<0.0001 | 18 | 4 |
<0.0001 | Low CD3/high c-kit or high CD3/low c-kit | 19 | 16 | 27 | 8 | 24 | 11 | High CD3/high c-kit | 3 | 20 | 8 | 15 | 7 | 16 |
|
CD3/VEGF | Low CD3/low VEGF | 17 | 3 |
<0.0001 | 18 | 2 |
<0.0001 | 16 | 4 |
<0.0001 | Low CD3/high VEGF or high CD3/low VEGF | 21 | 14 | 28 | 7 | 26 | 9 | High CD3/high VEGF | 2 | 23 | 9 | 16 | 7 | 18 |
|
c-kit/VEGF | Low c-kit/low VEGF | 10 | 2 |
<0.0001 | 12 | 0 |
0.002 | 11 | 1 |
<0.0001 | Low c-kit/high VEGF or high c-kit/low VEGF | 20 | 6 | 22 | 4 | 21 | 5 | High c-kit/high VEGF | 10 | 32 | 21 | 21 | 17 | 25 |
|
|
, number of samples; , statistical significance; NS, not significant.
|